Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Cancer|May 4, 2018
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study GroupDelphine Rea, Shanti Ame, Marc Berger, et al.
The New England Journal of Medicine|December 24, 2010
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, et al.
Leukemia Research|May 25, 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemiaMarie Balsat, Vincent Alcazer, Gabriel Etienne, et al.
The Lancet. Haematology|December 22, 2015
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 studyFranck E Nicolini, Gabriel Etienne, Viviane Dubruille, et al.
Nature Communications|June 8, 2018
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hubRocco Piazza, Vera Magistroni, Sara Redaelli, et al.
Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Nature Communications|November 24, 2020
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamineDiletta Fontana, Mario Mauri, Rossella Renso, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
British Journal of Haematology|October 10, 2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study)Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Cancer|May 4, 2018
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study GroupDelphine Rea, Shanti Ame, Marc Berger, et al.
The New England Journal of Medicine|December 24, 2010
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, et al.
Leukemia Research|May 25, 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemiaMarie Balsat, Vincent Alcazer, Gabriel Etienne, et al.
The Lancet. Haematology|December 22, 2015
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 studyFranck E Nicolini, Gabriel Etienne, Viviane Dubruille, et al.
Nature Communications|June 8, 2018
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hubRocco Piazza, Vera Magistroni, Sara Redaelli, et al.
Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Nature Communications|November 24, 2020
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamineDiletta Fontana, Mario Mauri, Rossella Renso, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
British Journal of Haematology|October 10, 2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study)Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, et al.
Pageof 11